3D Printed Medical Devices: Saving Lives but Do We Need More Regulation? by Dingman, Cherie Lynn
Seton Hall University
eRepository @ Seton Hall
Law School Student Scholarship Seton Hall Law
2015
3D Printed Medical Devices: Saving Lives but Do
We Need More Regulation?
Cherie Lynn Dingman
Follow this and additional works at: https://scholarship.shu.edu/student_scholarship
Part of the Law Commons
Recommended Citation
Dingman, Cherie Lynn, "3D Printed Medical Devices: Saving Lives but Do We Need More Regulation?" (2015). Law School Student
Scholarship. 820.
https://scholarship.shu.edu/student_scholarship/820
 1 
3D PRINTED MEDICAL DEVICES: SAVING LIVES BUT DO WE NEED MORE 
REGULATION? 
 
CHERIE-LYNN DINGMAN 
 
ABSTRACT 
 
 3D printing applications have evolved rapidly over the years, and are making their mark 
in the Medical Device Industry. In February of 2013, because of 3D printing, an Ohio family 
was given hope that their 6-week old baby, Kaiba, would make it out of the hospital alive. Kaiba 
was suffering from Tracheobronchomalacia, a respiratory condition that was causing his central 
airways to collapse. The doctors obtained emergency clearance from the Food and Drug 
Administration to create and implant a custom-made tracheal splint. They were able to take a CT 
scan of Kaiba’s lungs and create the splint using a 3D printer. Kaiba has not had a single 
breathing emergency since.  
 There are two pathways a medical device can take to market, the 510(k) premarket 
submission or the Premarket Approval process. Currently, 3D printed devices are receiving 
clearance through the 510(k) process. To receive 510(k) clearance, a medical device 
manufacturer must provide evidence that the new device is “substantially equivalent” (at least 
as safe and effective) to another legally U.S. marketed device. There are concerns with clearing 
these 3D printed devices through the current 510(k) process, as they have different technical 
considerations than standard medical devices. Therefore, to ensure patient and product safety, 
the FDA must implement new regulations or alter the existing framework to account for these 
customizable devices.  
 This Article will walk through the history of 3D printing and how the technology is 
currently being utilized in the medical device industry. It will then lay out the existing regulatory 
pathway for medical devices and demonstrate the concerns of clearing and approving 3D 
printed devices through this framework. Finally, the Article offers recommendations on the 
framework that should be put in place to regulate this remarkable scientific application.   
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I. INTRODUCTION 
 
 3D printing in the medical context is saving lives, quite literally. Day after day, the 
Gionfriddo family watched their 6-week old baby, Kaiba, stop breathing and have to be 
resuscitated over and over again. 1   Kaiba was suffering from Tracheobronchomalacia, a rare 
respiratory condition resulting from weak cartilage in the walls of the trachea and bronchi, 
ultimately causing his central airways to collapse. 2 The family was told by their doctors that 
there was a pretty high chance that Kaiba would not be leaving the hospital alive, and if it were 
not for 3-D printing, those doctors would have been right.3 The family traveled to a University of 
Michigan affiliated hospital, where the physicians were developing a b ioresorbable tracheal 
                                                 
1 David A. Zopf et al., Baby’s Life Saved with Groundbreaking 3D Printed Device from 
University of Michigan that Restored His Breathing, May 22, 2013, 
http://www.uofmhealth.org/news/archive/201305/baby%E2%80%99s- life-saved-
groundbreaking-3d-printed-device. 
2 Id.  
3 Id.  
 3 
splint that could be implanted in Kaiba to treat his condition. 4 The Hospital was able to obtain 
emergency clearance from the FDA to create and implant this splint for Kaiba. 5 Using a detailed 
CT scan of Kaiba’s lungs, the doctors were able to make a custom-designed device out of a 
biopolymer, polycaprolactone.6 The splint was then sewn around Kaiba’s airway to expand the 
bronchus and provide a skeletal framework to allow for proper growth. 7 Since the splint was 
made out of bioresorbable plastics, it will dissolve within three years, after the airway has grown 
back with greater strength. Since the implantation of the splint, Kaiba has not had a single 
breathing emergency.8 
 3D printing, also known as “additive manufacturing,” was first invented in the early 
1980s.9 At first this technology was solely being utilized in the industrial sector, specifically 
rapid prototyping and specialized manufacturing, however, slowly, it started working its way 
into consumer and education sectors as well.10 Most recently, and for purposes of this Article, the 
technology is being applied to all areas of science and medicine. Specifically, scientists are 
increasingly being able to use 3D printing to engineer human tissue, organs, and medical 
devices.11  
 This Article seeks to demonstrate that the current regulatory pathway, the 510(k) and 
Premarket Approval processes, under which 3D printed medical devices obtain clearance or 
approval, is insufficient to render reasonable assurance of safety and effectiveness of these new 
                                                 
4 Id.  
5 Id.  
6 Id. 
7 Id. 
8 Id. 
9 Carl Schubert et al., Innovations in 3D Printing: A 3D Overview from Optics to Organs, 98 
BRIT. J. OF OPHTHALMOLOGY 159 (2014). 
10 Id. 
11 Sean V. Murphy & Anthony Atala, 3D Bioprinting of Tissues and Organs, 32 NATURE 
BIOTECHNOLOGY 773 (2014). 
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devices. Part II of this Article lays out the current state of 3D printing, specifically addressing the 
processes and methods behind 3D printing as well as current medical applications using the 
technology. Part III addresses the FDA’s role in regulating medical devices, how the existing 
regulatory pathway is implemented, and concerns with that regulatory pathway pertaining to 3D 
printing applications. Lastly, Part IV of this article enumerates regulatory concerns specific to 
3D printing in the medical device industry.  
 Ultimately, this Article makes two recommendations. First, 3D printed medical devices 
are so different and unique from traditional medical devices that these applications need to be 
addressed by the FDA on a case-by-case basis. And because these applications are still in their 
infancy, it would be feasible for the FDA to follow this recommendation.  Second, more controls 
pertaining to inputs, such as the materials used, and outputs, meaning post-market implications 
need to be assessed and regulated extensively. Currently, with how the 510(k) and Premarket 
Approval processes are written, the FDA is not tasked with evaluating these factors, and as a 
result, it is highly unlikely that the FDA has a reasonable assurance of safety and effectiveness of 
these devices.   
 
II. CURRENT STATE OF 3-D PRINTING 
 
A. What is 3D Printing?  
 
 To provide a simplistic definition, 3D printing is a “manufacturing method in which 
objects are made by fusing or depositing materials – such as plastic, metal, ceramics, powders, 
liquids, or even living cells – in layers to produce a 3D object.”12 At this point in time, there are 
close to two- dozen 3D printing processes, all which use different methods and materials, making 
                                                 
12 C. Lee Ventola, Medical Applications for 3D Printing: Current and Projected Uses, 39 
PHARMACY AND THERAPEUTICS 704 (2014). 
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the information on the web describing the technology variable.13 To provide a generalization, the 
processes are able to construct a 3D object in any form, as defined in a computer-aided design 
(CAD) file.14  
 The user first must create a 3D printable-model using a 3D scanner and then convert the 
model into a CAD file using specific computer software. 15 In the device industry, professionals 
are using radiographic images (x-rays, MRIs, and CT scans) as 3D printable models and 
converting them into the CAD file.16  The 3D printer will then follow the instructions in the CAD 
file to build the foundation of the object, and continually print successive layers of the material 
to build the 3D object.17 Finally, these layers will be joined and fused together to create the final 
3D printed product.18 
  Charles W. Hull first invented the 3D printing method in 1984, labeling the method as 
Stereolithography (STL).19  When the technology was first developed, it was used in product 
development, data visualization, rapid prototyping, and specialized manufactur ing.20 However, 
the technology has evolved rapidly since then, making the 3D printing industry worth 
approximately $700 million.21 While the possibilities are endless, current applications include, 
but are not limited to, the following: apparel, automobiles, construction, firearms, medicine, art, 
education, and environmental use.22    
 
                                                 
13 Id. 
14 Id.  
15 Id. 
16 Id.  
17 Id. 
18 Id. 
19 Id. 
20 Schubert, supra note 9. 
21 Ventola, supra note 12. 
22 Ventola, supra note 12.  
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B. Medical and Health Aspects of 3D Printing 
 
 3D printing applications are not a new concept to medicine; they have been used to 
manufacture both dental implants and prosthetics since the early 2000s.23 However as of lately, 
current applications in the medical field have increased and are categorized into the following: 
“tissue and organ fabrication, creation of customized prosthetics, implants and anatomical 
models, and pharmaceutical research involving drug dosage forms, delivery, and discovery.”24 
The increase in applications is due to the many benefits of the technology as opposed to 
traditional manufacturing: customization, personalization, cost-effectiveness, and enhanced 
productivity. 25  However, with those benefits, also come concerns. The FDA has expressed 
numerous apprehensions regarding the technology such as mechanical properties, 
biocompatibility, and interactive design.26  
 There have been two instances in the U.S., where 3D printed medical devices have been 
cleared for commercial distribution. 27  Oxford Performance Materials (OPM), a company 
specializing in 3D printing, has received 510(k) clearance for two of its 3D printed devices. 28 In 
February 2013, OPM received 510(k) clearance for the OsteoFab Patient Specific Cranial 
Device.29 This was a noteworthy moment, as this product was the first 3D printed, non-metal 
implant to receive clearance from the FDA and it allows physicians to treat the highly complex 
                                                 
23 Ventola, supra note 12, at 706. 
24 Ventola, supra note 12, at 705-06.  
25 Ventola, supra note 12, at 705-06.  
26 Shana Leonard, FDA Grapples with Future Regulation of 3-D Printed Medical Devices, 
MEDICAL DEVICE AND DIAGNOSTIC INDUSTRY, June 13, 2014, 
http://www.mddionline.com/article/fda-grapples-future-regulation-3-d-printed-medical-devices-
140613.   
27 Chris Wiltz, The First FDA-Cleared, 3-D Printed Facial Implant, MEDICAL DEVICE AND 
DIAGNOSTIC INDUSTRY, Aug. 21. 2014, http://www.mddionline.com/article/first- fda-approved-3-
d-printed-facial-implant-140821.  
28 Id. 
29 Id.  
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anatomy of the brain and personalize a device for their specific patient. 30 In another triumphant 
success, on August 19, 2014, OPM received 510(k) clearance for its OsteoFab Patient-Specific 
Facial Device.31 OPM has made a remarkable contribution wit this device as well, as it  is the first 
and only cleared 3D polymeric implant for facial indications.32  
 While those two products are the only 3D printed devices that have obtained clearance 
through the 510(k) process, the FDA has approved others by “emergency clearance” for a 
specific, individual patient.33 In addition to the Gionfriddo family’s case in the Part I of this 
Article, C.S. Mott Children’s Hospital was able to save another child’s life with 3D printing. 
Garrett Peterson, an 18-month old baby, had spent his entire life in a hospital hooked up to 
ventilators, and there was no improvement being made. 34 Garrett was suffering from a condition 
called tetralogy of Fallot with absent pulmonary valve, which puts a tremendous amount of 
pressure on the airways. 35  As a result of this condition, he developed severe 
tracheobronchomalacia, which as stated previously, is a condition resulting from weak cartilage 
in the walls of the trachea and bronchi, ultimately causing his central airways to collapse. 36 
Sadly, the Petersons were unable to hold their own child due to the fear of compromising his 
breathing.37 They watched their baby turn blue in the face sometimes four to five times a day and 
                                                 
30 Id.  
31 Id. 
32 Cory Ziskind, Oxford Performance Materials Receives FDA Clearance for 3D Printed 
OsteoFab Patient-Specific Facial Device, Aug. 19, 2014, 
http://www.oxfordpm.com/news/article/2014-08-
19_oxford_performance_materials_receives_fda_clearance_for_3d_printed_osteofab_patient-
specific_facial_device.php.   
3 3  See Zopf, supra note 1.  
34 Mary Masson, Baby’s life saved after 3D printed devices were implanted at U-M to restore his 
breathing, Mar. 17, 2014, http://www.mottchildren.org/news/archive/201403/babys- life-saved-
after-3d-printed-devices-were- implanted-u.  
35 Id. 
36 Id. 
37 Id. 
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be resuscitated with heavy medications.38 “It’s really hard to watch your child basically suffocate 
and pass out before you could revive him and bring him back, over and over,” sad Jake Peterson, 
Garrett’s father.39  
 The doctors at C.S. Mott Children’s Hospital obtained emergency clearance from the 
FDA to create and implant a tracheal splint created from a biopolymer called polycaprolactone.40 
The doctors created a 3D model of Garrett’s airway using a CT scan of the trachea and bronchi 
and then created the splint for a customizable fit to Garrett’s bronchi. 41 From there, Richard G. 
Ohye, M.D., head of pediatric cardiovascular surgery, sewed two splints around the right and left 
bronchi to expand the airways and give it skeletal support to aid proper growth. 42 The body will 
reabsorb the splint, made out of a bioresorbable polymer, in three years, after proper airway 
growth is achieved.43   
 There have also been numerous successes surrounding 3D printed medical devices in 
Europe and Asia. I will touch on a few of the cases occurring in Europe to provide a better 
illustration of existing applications, however, for purposes of this paper, I solely focus on the 
regulatory framework surrounding medical devices in the United States.  
 In the UK, a patient had been diagnosed with a rare bone tumor called chondrosarcoma, 
which required the doctors to remove half of his pelvis. 44 Traditional implant device methods 
could have been used, replacing the patient’s pelvis with a hand-made device; however, these 
never fit perfectly, ultimately causing discomfort and medical issues for the patient down the 
                                                 
38 Id. 
39 Id. 
40 Id. 
41 Id. 
42 Id. 
43 Id.  
4 4  British surgeon uses 3D printing to create pelvis for a cancer patient , 3DERS.ORG, Feb. 10, 
2014, http://www.3ders.org/articles/20140210-british-surgeon-uses-3d-printing-to-create-pelvis-
for-a-cancer-patient.html.  
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road. 45The orthopedic surgeon, Craig Gerrard, scanned the patient’s pelvis to create a 3-D 
model, and a British medical device company was able to use this model to produce the half-
pelvis. 46  This 3-D printed implant was made out of titanium powder and was coated with a 
mineral that allowed the remaining bone to grow into the pores, ultimately enhancing the 
strength of the implant.47 Because of the material used and the precision of the 3D model, this 
technology is able to create devices more customizable to the patient.48  
 Similarly, a Dutch woman was suffering from an unfortunate condition known as 
Acromegaly, which results in the thickening of the skull and ultimately loss of essential brain 
functions. 49  Before 3D printing came into the mix, the woman was experiencing severe 
headaches, loss of vision, and motor skill depletion.50 It is common procedure in patients with 
Acromegaly to remove part of the skull temporarily to reduce pressure on the brain and then 
replace later with an implant that was made out of cement. 51  Unfortunately, these cement 
implants did not fit very well on the patients, which result in sub-par brain function for the 
patient.52 The doctors at University Medical Center Utrecht were able to manufacture a skull 
replacement made out of plastic with the help of an Australian medical device company.53 Three 
months post-surgery, the woman has no ruminants of pain and she has fully regained her 
vision.54 
                                                 
45 Id. 
46 Id. 
47 Id. 
48 Id.  
49 James Eng, Medical First: 3-D Printed Skull Successfully Implanted in Woman, NBC NEWS, 
Mar. 27, 2014, http://www.nbcnews.com/science/science-news/medical-first-3-d-printed-skull-
successfully- implanted-woman-n65576.  
50 Id. 
51 Id. 
52 Id. 
53 Id. 
54 Id.  
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III. EXISTING REGULATORY PATHWAY 
 
A. Role of FDA 
 The Food and Drug Administration (“FDA”) “is responsible for protecting the public 
health by assuring the safety, efficacy and security of human and veterinary drugs, biological 
products, medical devices, our nation’s food supply, cosmetics, and products that emit 
radiation.”55  To carry out that responsibility, under the Food Drug and Cosmetic Act (“FDCA”), 
the FDA is tasked with ensuring that there is a “reasonable assurance of the safety and 
effectiveness of devices intended for human use.”56  The term “medical device” is defined in the 
FDCA as: 
 An instrument, apparatus, implement, machine, contrivance, 
implant, in vitro reagent, or other similar or related article, 
including any component, part, or accessory, which is: (1) 
recognized in the official National Formulary, or the United States 
Pharmacopeia, or any supplement to them, (2) intended for use in 
the diagnosis of disease or other conditions, or in the cure, 
mitigation, treatment, or prevention of disease, in man or other 
animals, or (3) intended to affect the structure or any function of 
the body of man or other animals, and which does not achieve its 
primary intended purposes through chemical action within or on 
the body of man or other animals and which is not dependent upon 
being metabolized for the achievement of its primary intended 
purposes.57 
 
 For purposes of this Article, the salient aspects of this definition are intended for use in 
cure, mitigation, or treatment of the disease and intended to affect the structure or any function 
of the body.58 3D printed devices fall into the definition of “devices,” as they are similar to 
traditional devices. The devices are being used in the treatment of disease and/or are intended to 
affect the structure of the body. For instance, the tracheal splint mentioned in Part II of this 
                                                 
55 Food & Drug Admin., What We Do, http://www.fda.gov/aboutfda/whatwedo/ (last updated 
Aug. 5, 2014).  
56 Federal Food, Drug & Cosmetic Act, 21 U.S.C. §§393(b)(2)(C) (2006).  
57 Id. at §§321(h) (2006). 
58 Id. 
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Article was used in the treatment of tracheobronchomalacia to strengthen the bronchi and expand 
the airways, allowing for proper growth.59   
 Also worth noting, the last aspect of the definition, “which does not achieve its primary 
intended purposes through chemical action within or on the body and which is not dependent 
upon being metabolized for the achievement of its primary intended purposes,” is meant to 
separate devices from drugs.60 The FDA adopts the following definition of “chemical action” in 
their interpretation: “the formation or breaking of covalent or ionic bonds, and intermolecular 
forces are electrostatic interactions or forces resulting from the interaction of localized, short-
range electrical fields among atoms and/or molecules.”61 For purposes of medical devices, the 
Agency has determined that a device will achieve its purpose through a “chemical action” if the 
device either “(1) mediates a bodily response at the cellular or molecular level or (2) combines 
with or modifies an entity so as to alter that entity’s interaction with the body.”62 That being said, 
3D printed devices are not undergoing a chemical action within the body to achieve their 
intended uses. The 3D printing software and printer are producing a solid device that will be 
entering the body (similar to a standard medical device).  
B. Background of Device Regulation 
 In 1906, when the Pure Food and Drug Act was passed, medical devices did not pose a 
risk to the public since they were manufactured using obvious and simple mechanical 
                                                 
59 See Zopf, supra note 1.  
60 Federal Food, Drug & Cosmetic Act, 21 U.S.C. §§321(h) (2006). 
6 1  Food & Drug Admin., Interpretation of the Term “Chemical Action” in the Definition of 
Device Under Section 201(h) of the Federal Food, Drug and Cosmetic Act, June 2011 
http://www.fda.gov/RegulatoryInformation/Guidances/ucm259059.htm#what. 
62 Id.  
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processes. 63  However, beginning in the 1960s, medical devices began to receive a lot more 
attention from regulators as well as consumers. 64  As a result of such attention, the Cooper 
Commission (“the Commission”) was created in the late 60s and was responsible for “advising 
policy makers about improvements to the device regulatory system.” 65  The Commission 
proposed a risk-based approach to device regulation, which was adopted by the Medical Device 
Amendments of 1976 and is still the approach used today in assessing device applications.66 
However, recognizing that this risk-based regulatory scheme would take considerable time to 
implement and establish, Congress created the 510(k) process (addressed in Part C of this 
section) to accommodate those device that were close to being approved at the time, so as not to 
halt innovation. 67  
 The FDCA has been amended by both the Medical Device Amendments (MDA) of 1976 
and the Safe Medical Device Act (SDMA) of 1990. It incorporated the Commission’s risk-based 
approach in creating the three regulatory classes for medical devices: Class I, Class II, and Class 
III.68 A device is assigned to a specific classification based on the controls necessary to assure 
safety and efficacy, the intended use, and the indications for use. 69 The classification will also 
determine the type of premarketing submission required for FDA clearance or approval.70 
                                                 
63 Carol Rados, Medical Device and Radiological Health Regulations Come of Age, FDA 
CONSUMER MAGAZINE, Jan. – Feb. 2006, 
http://permanent.access.gpo.gov/lps1609/www.fda.gov/fdac/features/2006/106_cdrh.html.  
64 Ralph F. Hall & Michelle Mercer, Rethinking Lohr: Does “SE” Mean Safe and Effective, 
Substantially Equivalent, or Both? 13 MINN. J.L. SCI. & TECH. 737, 745 (2012). 
65 Id. 
66 Id.  
67 Id.  
68 Federal Food, Drug & Cosmetic Act, 21 C.F.R. §§860.3.  
69 Alena Allen et al., Food and Drug Law and Regulation 491 (David G. Adams eds., (2008). 
70 Id.  
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 Class I devices are the most simple devices and therefore are only subject to general 
controls.71 These devices are those that are not being used “in supporting or sustaining human 
life . . . or in preventing impairment of human health, and does not present a potential 
unreasonable risk of illness or injury.”72 Because of this low-risk level, the FDA has expressed 
that general controls are sufficient to assure the safety and efficacy of this Class. 73  General 
controls may include provisions that relate to establishment registration and device listing, 
premarket notification, records and reports, and good manufacturing practices. 74 Most Class I 
devices are exempt from Premarket Notification 510(k), however the manufacturers are still 
required to register and list the classification name of the device. 75 An example of a Class I 
device is an examination glove, elastic bandage, and in the case of 3D printing, external hearing 
aids have been placed in this Class since they are for external use.76 
 Next, Class II devices are medium-risk devices. The FDA has determined that general 
controls are insufficient to provide reasonable assurance of safety and effectiveness; therefore 
this Class is subject to both general and special controls. 77  Special controls may include 
postmarket surveillance, patient registries, development and dissemination of guidelines, and 
other appropriate actions, as FDA deems necessary to ensure safety and effectiveness. 78  An 
example of a Class II device is an infusion pump or a powered wheelchair.79 
                                                 
71 Federal Food, Drug & Cosmetic Act, 21 U.S.C. §§360c(a)(1)(A).  
72 Id. 
73 Id.; See also Hall, supra note 64, at 747.   
74 Food & Drug Admin., General Controls for Medical Devices, 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpeci
alControls/ucm055910.htm (last updated June 26, 2014).  
75 David S. Antzis et al., Bringing Your Medical Device to Market 140 (John B. Reiss eds., 2d 
ed. 2006).  
76 Hall, supra note 64, at 747.  
77 Federal Food, Drug & Cosmetic Act, 21 U.S.C. §§360c(a)(1)(B). 
78 Id.; See also Antzis, supra note 75.  
79 Antzis, supra note 75.  
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 Most Class II devices require Premarket Notification 510(k), in which the manufacturer 
must demonstrate that the new device is substantially equivalent to a legally marketed device 
(also known as “predicate device”).80 The FDA will make a determination that the new device is 
substantially equivalent if the new device has the same intended use and (1) the same 
technological characteristics as the predicate device, or (2) has different technological 
characteristics, however does not raise different questions of safety and effectiveness than the 
predicate device.81 
 Lastly, Class III devices pose the most risk to patients and therefore are subject to the 
strictest regulatory requirements. 82  These devices are those that are either: “(1) are used in 
supporting or sustaining human life or (2) are for a use which is of substantial importance in 
preventing impairment of human health or (3) present a potential unreasonable risk of illness or 
injury.”83 These devices cannot be classified as Class I or Class II because the FDA believes that 
there is insufficient information to suggest that general controls and special controls would 
provide a reasonable assurance of safety and effectiveness. 84 Most Class III devices are subject 
to Premarket Approval, however there are exceptions. If a Class III device is able to show that it 
is “substantially equivalent” to a legally marketed device, it may follow the 510(k) process until 
the FDA decides that that specific device category must submit a Premarket Approval 
application.85 
                                                 
80 Food & Drug Admin., Overview of Device Regulation, 
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ (last updated 
June 26, 2014). 
81 Federal Food, Drug & Cosmetic Act, 21 U.S.C. §§360c(i).  
82 Antzis, supra note 75, at 141.  
83 Allen, supra note 69, at 492.  
84 Federal Food, Drug & Cosmetic Act, 21 U.S.C. §§360c(a)(1)(C).  
85 Allen, supra note 69, at 492-93.  
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 As discussed above in Section II, Part B, the two instances in which the University of 
Michigan affiliated hospital created and implanted the tracheal splints; they obtained “emergency 
clearance” through the FDA.86 These devices were classified, as “custom devices,” which are not 
available for widespread distribution, and therefore are not subject to the device regulatory 
framework. A “custom device” is defined in the FDCA as: 
[A device] intended for use by an individual patient named in [an] 
order by such physician, dentist (or other specially qualified person 
so designated) and is to be made in a specific form for such patient, 
or . . . intended to meet the special needs of such physician or 
dentist (or other specially qualified person so designated) in the 
course of [his] professional practice . . . 87 
 
 Devices fall into this definition, and are exempt from the 510(k) clearance as well as the 
Premarket Approval process provided they are manufactured and produced with a specific 
patient in mind, will be used only on that patient, and are not going to be subject to widespread 
distribution.88 For purposes of this Article, it is very important to note that custom devices are 
different from customized devices. 89   A custom device is unique and manufactured for its 
intended use by a specific, named patient.90 To the contrary, a customized device is a “specific 
class of devices that is manufactured and available for commercial distribution, but can vary in 
size, shape or material on order of a physician to meet the needs of individual patients. 91 
Therefore, because customized devices are available for widespread dissemination, they are 
subject to the regulatory framework for medical devices.92   
 
                                                 
86 Zopf, supra note 1. See also Masson, supra note 34. 
87 Federal Food, Drug & Cosmetic Act, 21 U.S.C. §§360j(b).  
88 Allen, supra note 69, at 518.   
89 Allen, supra note 69, at 518.   
90 Allen, supra note 69, at 518.  
91 Allen, supra note 69, at 518.  
92 Allen, supra note 69, at 518.  
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C. Getting to Market 
 As a result of the MDA and SMDA, there are currently two different routes devices take 
to be approved for commercial distribution, the 510(k) process and the Premarket Approval 
process. To begin, the manufacturer should check the FDA Product classification Database to 
determine how their device is classified and then adhere to the regulations in determining the 
appropriate route to market.93  
i. 510(k) Process 
 Prior to commercial distribution, the manufacturer of non-exempt Class I and Class II 
devices must submit a 510(k) notification to the FDA. 94  Manufacturers must adhere to the 
regulations for guidance on the content required in their submission. 95  Specifically, the 
regulations state that the manufacturer must include the classification status of the device, 
proposed labeling, and information that demonstrates that the device is “substantially equivalent” 
to a pre-1976 marketed device, known as the “predicate device.”96  
 A predicate device is a device: (1) that was approved prior to May 28, 1976, the passage 
of the MDA, and for which a Premarket Approval is not required; (2) that has been reclassified 
from Class III to Class II or Class I; or (3) that has been found to be “substantially equivalent” 
through the 510(k) process.97 The FDA is flexible when making a determination that a device is 
“substantially equivalent” to a predicate device, in order to promote innovation and evolving 
                                                 
93 Food & Drug Admin., Product Classification, 
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technology. 98 That being said, it is possible for the new device to have certain characteristics 
that are substantially equivalent to one predicate device and others that are substantially 
equivalent to a different predicate device.99  
 If a manufacturer submits a 510(k) application for a 3D printed device, which will come 
into direct contact with the patient (almost always the case with 3D printed devices), the 
manufacturer must report the exact materials that will come into contact with the patient and if 
they are materially different from what the predicate device is comprised of. 100 If the materials 
are identical to the predicate device, the process ends there. However, if the materials, processes, 
or intended uses are not identical, biocompatibility testing (commonly known as “biological 
evaluation”) must be completed. 101  Biological evaluation is required to address potential 
toxicities that would occur as a result of contact with body.  102  To complete the testing 
successfully, the device must prove that the comprised materials do not: (1) produce adverse 
effects; (ii) produce carcinogenic effects; or (iii) produce adverse reproductive/developmental 
effects.103 If any risks from the materials are found during this testing, the manufacturer must 
demonstrate that the benefits will greatly outweigh the potential risks.104 For our purposes, 3D 
printed devices will have different materials and processes than predicate devices, so 
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manufacturers will have to undergo biological evaluation to ensure the new device is safe and 
effective for its intended use.   
  Once the 510(k) notification has been completed and submitted, the FDA will issue an 
order within 90 days on whether the new device is “substantially equivalent” or “not 
substantially equivalent” to the predicate device. 105 If the device is found to be “substantially 
equivalent” the device is cleared for commercial distribution.  106  The new device is then 
classified into the same class and subject to the same requirements and controls as the predicate 
device.107 The manufacturer must not to commercially distribute the device until the order is 
received. If the device is found to be “not substantially equivalent” to the predicate device, the 
new device is classified into Class III as a default, and must submit a pre-market approval 
(“PMA”) application.108  
ii. Premarket Approval Process 
 Typically, Class III devices, as well as some Class II devices, require a Premarket 
Approval (PMA) submission because there is not sufficient information to assure safety and 
effectiveness solely through general and special controls. 109  The PMA process is the most 
rigorous process for a medical device, both in terms of time and money. The submission must 
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contain valid and robust scientific evidence to provide reasonable assurances to the FDA that the 
device is safe and effective for its intended use. 110 
  First, the manufacturer must submit the PMA application, which is very specific and 
extensive, outlined in the statute and regulations. 111 The application must include: (1) Name and 
address of the applicant; (2) A table of contents; (3) A summary of the data and information 
supplied in the application; (4) A complete description of the device, including ingredients, 
proprieties, principles of operation, and facilities used; (5) Reference to any performance 
standard under the FDCA or the Radiation Control for Health and Safety Act of 1968 that is 
relevant to the safety and effectiveness of the device; (6) Data and information regarding 
nonclinical and clinical studies; (7) Any other information relevant to sa fety and effectiveness of 
the device; (8) Samples of the device, if requested; (9) Proposed labeling; (10) An environmental 
assessment; (11) A financial statement and/or disclosure statement; and (12) Any other 
information deemed necessary by the FDA.112  
 Specifically and most importantly, the information provided regarding nonclinical 
laboratory studies and clinical trials will play a significant role in whether the FDA chooses to 
approve or deny the application.113 Nonclinical studies include “microbiologica l, toxicological, 
immunological, biocompatibility, stress, wear, shelf life, and other laboratory or animal tests as 
appropriate.”114 Pursuant to these studies, the manufacturer must submit certification they were 
conducted in compliance part 58 of the regulations.115  
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 Next, the section pertaining to clinical trials must include, among other things, clinical 
protocols, number of investigators and subjects per investigators, subject selection, safety and 
effectiveness data, adverse events, etc.116 The manufacturer is also responsible for submitting 
certification that this study was conducted in compliance with IRB regulations or if not subject to 
those regulations, that it was conducted in compliance with informed consent regulations. 117  The 
main difference between the 510(k) and PMA processes is the requirement for clinical trials to 
prove safety and efficacy. In order to engage in clinical evaluation of devices, an investigational 
plan must be approved by an IRB and the IDE must be approved by the FDA. 118  “An 
investigational device exemption (IDE) allows the investigational device to be used in a clinical 
evaluation in order to collect safety and effectiveness data” required in a PMA application.119 
The manufacturer must also obtain informed consent from all patients, submit labeling stating 
that the device is for investigation use only, monitor the study and maintain records and 
reports.120  
 Once the FDA receives the application, they will review the contents to ensure 
completeness and conformity with the formal requirements explained above.121 Within forty-five 
(45) days of receipt, the FDA will notify the manufacturer whether the application has been 
“filed,” meaning it has met the threshold of completeness. 122 From there, the FDA has 180 days 
from the date of the filing to approve or deny the application, however, in practice this timeframe 
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is considerably longer.123 It is important to note, the manufacturer’s responsibilities do not end 
here. During this waiting period, PMA applicants have an affirmative duty to periodically update 
their pending application with new safety and effectiveness information learned about the device, 
in order to allow the FDA to make an informed decision regarding their device. 124  As shown, the 
PMA process takes a considerable amount of time compared to other methods of pre-approval, 
such as the 510(k) process. To illustrate, on average it will take several hundred days for the 
FDA to respond to a PMA, where the 510(k) process usually takes about 90-100.125  
D. Criticisms of the 510(k) process 
 The 510(k) process was initially developed in the late 1960s and revised in 1990 as a 
result of the SMDA of 1990.126 While the SMDA made worthy additions to the process, medical 
device innovation has evolved tremendously since the 1990s. Technological innovation and 
corroboration between medical institutions and manufacturers has changed greatly over the 
years, warranting a new and improved system of premarket approval and postmarket checks. As 
a result of the increasing innovation, the 510(k) process has been intensely criticized as not 
ensuring safety and effectiveness among medical devices.  
i. Institute of Medicine Review  
 Among one of those criticisms is a consumer study showing that devices cleared through 
the 510(k) process make up a large share of serious recalls on medical devices, as opposed to 
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devices approved through the PMA process. 127  In 2011, in response to that study, the FDA 
requested the Institute of Medicine (IOM), an independent organization which provides advice to 
decision makers, to review the 510(k) process to determine if it was allowing the FDA to 
accomplish its goal of ensuring safety and effectiveness. 128 The IOM was asked to answer two 
questions: (1) Does the current 510(k) process protect patients and promote innovation in support 
of public health? And (2) If not, what legislative, regulatory, or administrative changes are 
recommended to achieve the goals of the 510(k) process optimally?129  
 In their analysis, the IOM looked at numerous factors such as the legislative history of the 
510(k) process, the resulting framework, how the process is currently implemented, postmarket 
information on safety and effectiveness, and many more. 130 After reviewing such factors, the 
committee drew two conclusions: (1) the current 510(k) program lacks the statutory basis to 
make it a reliable premarket screen for safety and effectiveness of Class II devices and (2) it is 
unclear whether the 510(k) clearance process is facilitating or inhibiting innovation.131 
 Regarding the first conclusion, the committee found that the 510(k) clearance process is 
not intended to evaluate the safety and effectiveness of medical devices, and therefore, the 
process cannot be adequately transformed into a “premarket evaluation of safety and 
effectiveness” so long as the standard of “substantial equivalence” still exists.132 The committee 
explicitly states they are “not suggesting that all, many, or even any medical devices cleared 
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through the 510(k) clearance process and currently on the market are unsafe or ineffective,” 
however there is insufficient information to support highly confident conclusions regarding 
safety and effectiveness.133  
 The Center for Devices and Radiological Health (CDRH) and the FDA both enumerate 
two goals of the 510(k) clearance process: (1) to assure devices are safe and effective and (2) to 
promote innovation in the medical device industry. 134  However, both of these goals are 
inconsistent with the purpose that Congress laid out in the 510(k) program. By law, the 510(k) 
process focuses solely on the determination of a device’s “substantial equivalence” to a predicate 
device. In that regard, it is imperative to note that devices on the market prior to the enactment of 
the MDA of 1976 (those devices involved in substantial equivalence comparisons) have never 
been systematically assessed to determine their safety and effectiveness. 135  The risk-based 
classification system was developed in 1976, and these predicate devices were placed in the 
classes, however, they were never reassessed for safety and effectiveness under the revised 
FDCA. 136  Therefore, because the predicate device was not itself reviewed for safety and 
effectiveness, the committee found that clearance of a 510(k) submission was not a 
determination that the cleared device was safe or effective.137  
 Regarding the second conclusion, the committee found that there is no information 
illustrating whether the 510(k) process facilitates or inhibits innovation in the medical device 
industry.138 The committee defines innovation broadly as improving the quality of, efficiency of, 
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or access to health care.139 While it is found that the 510(k) is a faster and more efficient route to 
market, as opposed to the PMA process, the committee found that demonstrating substantial 
equivalence to a predicate device is not a scientific means of adapting to new technology. 140 
Ultimately, FDA’s implementation of the process, not the process itself, has stifled innovation 
due to the lack of transparency and predictability, which has led to an adverse effect on 
investment in future medical device development. 141 The committee believes that the FDA’s role 
in facilitating innovation is to create a regulatory framework that sets thresholds stringent enough 
to satisfy its own objective – medical devices cleared for commercial distribution will be safe 
and effective.142 Ultimately, the committee concluded that the FDA should move away from the 
510(k) process as soon as possible and implement a framework that allows for premarket and 
postmarket review to assure safety and effectiveness through the device’s life cycle.143  
ii. The Predicate Creep 
 Another common criticism of the 510(k) process is the “Predicate Creep.”144 As laid out 
above, devices are cleared through the 510(k) process if they are deemed “substantially 
equivalent” to a predicate device.145 However, devices are allowed to be substantially equivalent 
to one predicate device for one characteristic, and to another predicate for another 
characteristic.146 This creates the concern of the “Predicate Creep.”147 This danger arises from 
the “repeated cycle of slight component changes from predica te device to predicate device, 
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which leads to uncertainty in the clinical risks and benefits of the device” and possibly putting 
patients in danger.148  The ability to use multiple predicate devices creates significant problems 
because you are comparing a device piece-meal instead of comparing the entire device to a 
predicate.149  
 The FDA has responded to this criticism by stating that this is not an adequate concern 
since the new device is simply combining the functionality of two predicates. 150 However, this 
logic fails where mixing the two predicate creates a device with uncertain risks and benefits.151 
Put simply, because of this process, manufacturers are able to bypass significant and important 
clinical trials and ultimately pass the risk to the public. To illustrate the popularity of the 510(k) 
process, about 98% of devices obtain clearance through the 510(k) process, the remaining 2% 
going through the PMA process. 152  The 510(k) is clearly the preferred route to market for 
devices, even when the appropriate route would be the PMA process. 153  
 
IV. REGULATORY CONCERNS IN 3D PRINTING 
 
 As stated earlier, the 3D printing industry is currently worth about $700 million, with 
only 2% being spent in the medical device industry. 154 However, the 3D industry is expected to 
grow into an $8.9 billion industry in the next 10 years, and it is predicted that 21% will be spent 
on medical applications. 155  That being said, while only two 3D printed devices have been 
approved through the 510(k) process, it is likely that those numbers will also increase in the 
years to come. And while the current 510(k) process may be appropriate for traditional devices, 
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although this has rebutted in Section III, Part C, in Criticisms of the 510(k) Process, it is a very 
dangerous framework for regulating 3D printed devices.  
 As stated in Section III, Part C, non-exempt Class I as well as Class II devices must 
obtain clearance through the 510(k) program prior to widespread distribution of their devices. 156 
To obtain clearance, the manufacturer must demonstrate that the new device is “substantially 
equivalent” to a predicate device.157 A predicate device is any of the following: (1) A device that 
was approved prior to May 28, 1976, for which a PMA is not required ; (2) A device which has 
been reclassified from Class III to Class II or Class I; or (3) A device which has been found to be 
“substantially equivalent” through the 510(k) process. 158  There are a couple different reasons 
why it is troubling that a 3D printed device could be found to be “substantially equivalent” to 
such predicate device through the 510(k).  
 First and foremost, to be categorized as “substantially equivalent” the device must have 
the same intended uses as the predicate device and either (1) have the same technological 
characteristics or (2) if there are new technological characteristics; the new device must be as 
safe and effective as the predicate.159 Being that 3D printed devices use a completely different 
process, known as “additive manufacturing,” than that used to manufacture traditional devices, 
these device automatically fall into the second category of having different technological 
characteristics. Therefore, to be proven “substantially equivalent,” they would need to 
demonstrate that they have no new safety concerns. However, this is not possible. 3D printed 
devices are using raw materials, such as powder, plastic, paper, etc. that are coming into contact 
with the body, therefore safety concerns arise that must be tested. It is inappropria te for the FDA 
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to label these devices “as safe and as effective” as a traditional device just because they have the 
same intended use.  
 Second, if the manufacturer is comparing the new 3D printed device to a predicate device 
that was approved prior to May 28, 1976, there are low assurances that this device will be 
“substantially equivalent” or even worse, safe and effective. This assertion is made in reference 
to the IOM report in 2011.160 Devices that were approved prior to May 28, 1976 (the enactment 
of the MDA) have not undergone assessment by the FDA to determine their safety and 
effectiveness, therefore the only real evidence of their safety and efficacy is the benefits and risks 
displayed from the public. 161 While this would not be as grave of a concern if we were dealing 
with traditional devices, 3D printed devices that have different material and technical processes, 
which create uncertainty. It is illogical to say that a 3D printed device is substantially equivalent 
or “as safe and effective” as a device pre-1976 that has not been properly tested for safety and 
effectiveness.  
 Furthermore, the PMA process is also not an appropriate check of safety and 
effectiveness for 3D printed devices. The crutch of the PMA process is nonclinical and clinical 
trials in order to establish safety and effectiveness of the device. 162 However, well it may seem 
logical at the moment to mandate 3D printed devices go through the PMA process; it will be 
difficult for manufacturers to complete the clinical trial requirement. The PMA application 
requires that the manufacturer submit a summary of the clinical investigations involving human 
subjects involved, selection criteria, study population, study period, adverse reactions and 
complications, etc.163 It will be impossible for a 3D medical device manufacturer to satisfy these 
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regulation requirements, as the patient population of their device will most likely be one, since it 
is a customizable device. Therefore, while the PMA process may provide greater assurances of 
safety and effectiveness, due to the technological nature of manufacturing 3D printed medical 
devices, it is not the appropriate process for these devices.  
 
V. RECOMMENDATIONS 
 
 While the 3D printing technologies have been around since the 80s, 3D printed medical 
devices are just gaining momentum. The applications offer significant benefits such as 
customization, personalization, cost-effectiveness, and enhanced productivity.164 However, with 
every great technology, come concerns, that our regulatory framework must take into account. I 
have addressed those concerns with the 510(k) and PMA process in this Article. That being said, 
I have two recommendations regarding the future regulation of 3D printed medical devices. First, 
while the technology is still in its infancy, I would suggest that the FDA continue to address 
applications on a case-by-case basis. However, as the applications increase, it will not be feasible 
to address on a case-by-case basis, which brings me to my second recommendation. I would 
suggest adding controls specifically tailored to 3D printed devices, to address concerns that 3D 
printed devices are substantially different from standard medical devices.  
A. Case-by-Case Review 
 
 3D printing is not a new concept to our society; it has been regulated since the 1980s. 
However, it is currently gaining attention in the medical sector. There are currently two medical 
devices, the OsteoFab Cranial Device and OsteoFab Facial Device, which have achieved FDA 
clearance through the 510(k) process and are currently being marketed for widespread 
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distribution. 165  In my opinion, these devices were wrongly classified as “substantially 
equivalent” to devices that had the same intended use, as the 3D printing process was not taken 
into account during that assessment.  
 On the other hand, two 3D printed tracheal splints have been created and implanted at a 
University of Michigan affiliated hospital and were approved through emergency clearance, 
since they were classified as a “custom device.” 166  These devices are not approved for 
commercial distribution; they are solely used for the individual patient named in the order. While 
this Article focuses on devices that will be introduced into the commerce scheme, I would argue 
that the FDA should treat every 3D printed device as they did the tracheal splints during 
emergency clearance. These devices are reviewed on a case-by-case basis and do not bypass a 
“safety and effectiveness” assessment, being that there is no “substantial equivalence” standard 
in the emergency clearance process. 
 It will be feasible to address applications on a case-by-case basis right now because 3D 
printing in the medical device industry is still in infancy stages. The FDA is currently reaching 
out to stakeholders to obtain input regarding a future regulatory framework, so it seems they are 
not completely satisfied with using the 510(k) or PMA processes either. They held a workshop in 
October and received valuable input regarding the technical considerations of this application. In 
the years to come, there will need to be an established regulatory framework to address 3D 
printed devices, which will lead me to my second recommendation.  
B. Specialized Controls 
  
 My second recommendation is to implement specialized controls pertaining to 3D printed 
devices. I agree with the IOM Report (referenced in Section III, Part C) that with the way the 
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510(k) program is written, there is no “safety and effectiveness” testing done on the new 
device.167 However, should the FDA choose to stay with the 510(k) process for the time being, I 
would argue that additional controls would ease the minds of the public and industry. 
 3D printed devices that meet the custom device exemption, which are intended for use by 
a specific patient and are not being made available for commercial distribution, are not subject to 
the medical device regulatory framework described throughout this Article, and therefore we 
need not address their controls.168  However, for purposes of 3D printed devices that will be 
subject to either the 510(k) or PMA process, there needs to be sufficient checks in place to assure 
safety and effectiveness.  
 Devices cleared under the 510(k) process are regulated by both general controls and 
special controls in order to ensure the safety and effectiveness of the device. 169 General controls 
include checks such as records and reports and good manufacturing practices. 170 And special 
controls may include postmarket surveillance, dissemination of guidelines, and any other 
appropriate actions deemed necessary by the FDA. 171 All of these controls are relating to the 
process of manufacturing the device. However, in the case of 3D printed devices, we need to 
focus on the materials comprising the device, in addition to the process, as the materials are what 
is creating safety concerns in the eyes of the FDA and the public. 
 Devices approved through the PMA process must undergo clinical trials to demonstrate 
that the new device is both safe effective.172 As stated in Part IV, it is impossible for a 3D device 
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manufacturer to satisfy the clinical trial requirements comprising the PMA process, since the 
device has a patient population of one, being that it is a customizable device. A way to maneuver 
around this requirement and still complete the PMA process would be to require clinical trials on 
the process itself, instead of the product. The manufacturer would be required to show that the 
manufacturing process is itself safe and repeatable throughout all manufactured devices, 
regardless of the patient customization. This validation in conjunction with the additional 
specialized controls would be an appropriate course of action to ensure safety and effectiveness 
of these devices.   
 
VI. CONCLUSION 
 
 3D printing, while it may seem years off to most, is gaining momentum in the Medical 
Device Industry. The technology is being used right now to create non-functional replacements 
such as tracheal splints, skulls, hips, etc., however, scientists and healthcare profess ionals are 
also in the process of using the technology to create functional organs such as hearts and 
kidneys. While I assume that by the time these functional organs are viable for distribution, the 
FDA will have established a more robust approval process, there is no harm in implementing the 
process right now to allow for consistency and predictability in FDA approval.  
 When the Medical Device Amendments of 1976 were enacted, Congress recognized that 
they would take some time to implement, and thus came up with the 510(k) process so as not to 
stifle device innovation and penalize those manufacturers that were close to approval pre-
MDA.173 The same concern should be recognized right now. We are not far off from being able 
to develop functional organs using 3D printing, and yet, there is no regulatory framework robust 
enough to ensure the safety and effectiveness among these products. Unfortunately, if the system 
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is not reworked to accommodate for 3D printed device, those functional organs, which require 
more quality control than standard devices, will either be cleared through the relaxed 510(k) 
process, or those innovations, which could save lives, will be halted to ensure implementation of 
the new approval process. It’s a lose-lose. There needs to be immediate action from the FDA to 
address this remarkable scientific advancement.   
